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Introduction {#sec1}
============

Clathrin-mediated endocytosis (CME) is the best-characterized route of internalization for plasma membrane (PM)-resident proteins, thereby regulating a variety of cellular functions ranging from metabolism to signaling and neurotransmission ([@bib56], [@bib37]). In mammalian cells, adaptor protein 2 (AP2) is the most abundant clathrin adaptor, involved in the early phase of clathrin-coated pit (CCP) nucleation and maturation ([@bib56], [@bib37], [@bib43]). As CCPs gain curvature and mature, AP2 recruits cargoes. This step represents an "endocytic checkpoint," as failure to recruit cargo results in short-lived, abortive CCPs ([@bib33], [@bib35], [@bib1], [@bib13], [@bib28], [@bib39], [@bib40], [@bib55], [@bib20]). Fission of cargo-loaded, deeply invaginated CCPs is executed by the GTPase dynamin, leading to the release of clathrin-coated vesicles (CCVs) (for a review see [@bib3]). Although clathrin, AP2, dynamin, and cargo constitute the basic components of a CCP, a variety of accessory proteins have been implicated in the assembly and in the maturation of CCPs ([@bib34], [@bib37], [@bib44], [@bib46]).

AP2 is highly conserved from yeast to human ([@bib62], [@bib50], [@bib36]). Notably, it is not essential for viability or for CME in yeast, and other adaptors can substitute for it ([@bib41], [@bib10], [@bib72]). Moreover, differently from mammalian cells, CCP nucleation in yeast does not require AP2 binding motifs in the cargo cytosolic tail (e.g., Yxxφ), while ubiquitination of cargo and adaptors is critical ([@bib72], [@bib73]). In contrast, AP2 is indispensable for embryonic development of *Drosophila*, *C. elegans*, and mice ([@bib26], [@bib48], [@bib24]), and it is thought to be essential for CCP nucleation in mammalian cells ([@bib14]). Most studies in mammalian cells have focused on constitutive endocytosis (see, e.g., [@bib1], [@bib14], [@bib40]), mainly using transferrin receptor (TfR) as model cargo, for which AP2 appears to be essential ([@bib9], [@bib39], [@bib46], [@bib30], [@bib29], [@bib49]). In contrast, ligand-induced receptor internalization might occur in the absence of AP2, as AP2 knockdown (KD) experiments have shown that the internalization of some signaling receptors can still occur under conditions of functional AP2 ablation ([@bib32], [@bib42], [@bib30], [@bib29], [@bib49]).

From these latter observations, it appears that AP2-independent mechanisms of CME also exist in mammalian cells. The issue, however, is debated and far from being settled for two main reasons: (1) it cannot be excluded that residual levels of AP2 in the KD experiments are indeed responsible for the residual CME, and (2) under unperturbed conditions, no conclusive imaging-based evidence has been produced showing that a significant fraction of clathrin-dependent internalization events occur in the absence of AP2 in the forming pit.

The issue is of particular relevance for those signaling receptors, such as epidermal growth factor receptor (EGFR), which might be internalized via AP2-dependent and AP2-independent CME ([@bib30], [@bib29], [@bib49]), also considering the large variety of endocytic factors and internalization and sorting signals involved in EGFR endocytosis ([@bib22]). These considerations highlight a number of unresolved questions. (1) Do different modalities of CME exist under physiological conditions? (2) Are they cargo selective? (3) Are they differentially coupled to receptor fate and/or signaling? The present studies were undertaken to address these questions.

Results {#sec2}
=======

A Subclass of Short-Lived CCPs Lacking AP2 {#sec2.1}
------------------------------------------

To investigate whether different subclasses of clathrin-coated structures (CCSs), characterized by the presence versus absence of AP2, exist under physiological conditions, we used SUM159 cells that were gene-edited to express AP2σ2-EGFP and CLTA-TagRFP (see [STAR Methods](#sec4){ref-type="sec"}). We monitored CCS dynamics by live total internal reflection fluorescence (TIRF) microscopy as previously described ([@bib1], [@bib14]). In this analysis, we adopted a rather stringent cutoff by excluding events that were highly motile with an initial mean square displacement (MSD) larger than 0.01 μm^2^ ([Figure 1](#fig1){ref-type="fig"}A). This was done to minimize the contribution of CCVs originating from the secretory pathway. Under these conditions, 30%--40% of all detected events were computed. We found that 55%--70% of these clathrin-positive events (excluding events below 20 s and above 120 s in duration) were also positive for AP2, while the rest lacked the AP2 signal ([Figure 1](#fig1){ref-type="fig"}A). All the recorded events, presumably membrane bound and termed here CCPs, were grouped in cohorts with a specific range of lifetimes ([Figure 1](#fig1){ref-type="fig"}B). This revealed that although clathrin+/AP2+ events were almost equally distributed in the lifetime cohorts between 20 and 80 s, the clathrin+/AP2− events were enriched in the cohorts with shorter lifetime (20--38 s). This argues for the existence, under physiological conditions, of a subclass of endocytic CCPs lacking AP2, which are generally short lived and smaller than AP2-containing CCPs, while displaying a similar intensity-growth profile and comparable dynamics. Of note, when the MSD threshold for inclusion was raised to 0.0155 or to 0.02 μm^2^, results superimposable to those described above were obtained ([Figure S1](#mmc1){ref-type="supplementary-material"}).Figure 1Live TIRF Imaging of CCPs in SUM159 and AP2-WT MEF Cells(A) Cumulative frequency distribution of the initial mean square displacement (MSD) of clathrin-coated structures containing or not AP2 in SUM159 cells imaged by TIRF. Clathrin events with initial MSD larger than 0.01 μm^2^ (dotted line) were excluded from the plots displaying fluorescence intensity cohorts (B).(B) Automated analysis of clathrin-coated structure formation at the plasma membrane of SUM159 cells obtained from 13 cells and ∼350 clathrin traces. The analysis for traces excluding events with lifetimes \< 20 s shows average fluorescence intensity plots (mean ± SD) grouped as cohorts according to their lifetimes. The left panel corresponds to 235 events containing CLTA-TagRFP and AP2-σ2-EGFP (clathrin+/AP2+), while the right panel corresponds to 112 events devoid of AP2-σ2-EGFP (clathrin+/AP2−).(C) Cumulative frequency distribution of the initial MSD of clathrin-coated structures containing or not AP2 in MEF AP2-WT cells imaged by TIRF. Clathrin events with initial MSD larger than 0.01 μm^2^ (dotted line) were excluded in the plots displaying fluorescence intensity cohorts (D).(D) Automated analysis of clathrin-coated structure formation at the plasma membrane from 8 cells and ∼670 clathrin traces from MEF WT cells.(E) Representative TIRF microscopy time series acquired every 2 s from the bottom surface of MEF cells, stably expressing clathrin light chain A tagged with TagRFP (CLTA-TagRFP) together with σ2 of AP2 tagged with EGFP (AP2σ-EGFP). The TIRF snapshots (left) were recorded at 224 and 138 s, and the corresponding right panels are kymographs from the complete time series. The yellow tracings display the path used to generate the kymographs. The green channels in the kymographs were shifted upward by 5 pixels. The majority of the endocytic clathrin structures contained clathrin together with AP2 in the WT cells (e.g., pits 1 and 4), and few contained only clathrin (e.g., pits 2 and 3).

Next, used mouse embryonic fibroblasts (MEFs) derived from AP2μ conditional knockout (KO) mice (AP2μ^fl/fl^, henceforth AP2-WT \[wild-type\]; [Figure S2](#mmc1){ref-type="supplementary-material"}A; [@bib69], [@bib38]). These cells were engineered to stably express AP2σ2-EGFP and CLTA-TagRFP as transgenes (see [Figures S2](#mmc1){ref-type="supplementary-material"}B and S2C and their legends for details). In this model, before CRE treatment (AP2-WT cells), we confirmed the phenotypes observed in SUM159 cells; in particular, we could detect about one-third of the clathrin-positive events that lacked the AP2 signal ([Figures 1](#fig1){ref-type="fig"}C--1E). Importantly, these events fell mainly in the short-lived cohort of CCPs ([Figures 1](#fig1){ref-type="fig"}C--1E; see also [Figures S2](#mmc1){ref-type="supplementary-material"}D and S2E, left and center). In contrast, fewer than 1% of all the AP2-positive events lacked clathrin (clathrin−/AP2+).

Treatment of AP2-WT MEFs with CRE recombinase induced the excision of exons 2 and 3 of the *Ap2m1* gene (henceforth AP2-KO; [Figure S2](#mmc1){ref-type="supplementary-material"}A) and the loss of AP2μ protein expression ([Figures 2](#fig2){ref-type="fig"}A and 2B). In AP2-KO MEFs, clathrin-positive events persisted, with frequency and cohort distribution resembling those observed for the AP2-negative CCPs in AP2-WT cells ([Figures 2](#fig2){ref-type="fig"}C--2E; see also [Figures S2](#mmc1){ref-type="supplementary-material"}D and S2E, right). These data argue that a subset of CCPs can form also in the complete absence of AP2.Figure 2Live TIRF Imaging of CCPs in AP2 KO MEF Cells(A) MEFs from conditional AP2μ^fl/fl^ mice ([Figure S2](#mmc1){ref-type="supplementary-material"}A) were treated *in vitro* with CRE recombinase, as indicated, followed by immunoblotting (IB) as shown. The lower band in the AP2μ IB is nonspecific; the specific AP2μ band is indicated by an arrow. In all subsequent experiments, AP2μ^fl/fl^ MEFs were either left untreated or treated with CRE for 14 days-two rounds (henceforth referred as AP2-WT and AP2-KO, respectively).(B) AP2-WT and AP2-KO MEFs were analyzed for mRNA levels of *Ap2m1* and *Cltc* using qRT-PCR. mRNA levels are reported relative to untreated controls and normalized to the *18S* gene. Error bars are calculated on technical replicates (n = 3).(C) Cumulative frequency distribution of the initial MSD of clathrin-coated structures in MEF AP2-WT and AP2-KO cells imaged by TIRF. Clathrin events with initial MSD larger than 0.01 μm^2^ (dotted line) were excluded in the plots displaying fluorescence intensity cohorts (D).(D) Automated analysis of clathrin-coated structure formation at the plasma membrane from 12 cells and ∼439 clathrin traces from MEF KO cells.(E) Representative TIRF microscopy time series acquired every 2 s from the bottom surface of MEF AP2-KO cells, stably expressing CLTA-TagRFP together with AP2σ-EGFP. The TIRF snapshots (left) were recorded at 224 and 138 s, and the corresponding right panels are kymographs from the complete time series. The yellow tracings display the path used to generate the kymographs. The green channels in the kymographs were shifted upward by 5 pixels. Endocytic "clathrin-only" structures are present (e.g., pits 1 and 2).

Morphological Analysis of CCPs Formed in AP2-KO MEFs {#sec2.2}
----------------------------------------------------

We performed electron microscopy (EM) of PM sheets prepared from AP2-WT and AP2-KO MEFs. This confirmed that CCSs form in the absence of AP2 ([Figure 3](#fig3){ref-type="fig"}A). The surface density of CCS was reduced by ∼80% in AP2-KO MEFs versus AP2-WT ([Figure 3](#fig3){ref-type="fig"}B, top). However, the cell surface area of AP2-KO MEFs was greatly enlarged versus AP2-WT (∼2.5-fold surface increase; [Figure S3](#mmc1){ref-type="supplementary-material"}A). When normalized for cell surface area, AP2-KO MEFs showed a ∼50% decrease in CCSs versus controls ([Figure 3](#fig3){ref-type="fig"}B, bottom). Importantly, the disappearance of large and medium CCSs (including flat clathrin lattices and plaques; [@bib25], [@bib58]) and a shift toward smaller structures (≤0.03 μm^2^) were observed in AP2-KO MEFs ([Figure 3](#fig3){ref-type="fig"}C, left), as also previously shown in AP2-KD HeLa cells ([@bib47], [@bib49]). Analysis of the area distribution of the CCSs with size ≤ 0.03 μm^2^ showed that AP2-KO MEFs had lost larger CCSs, while retaining the smaller ones, with compared to WT cells ([Figure 3](#fig3){ref-type="fig"}C, right), as also confirmed by transmission EM (TEM) ([Figure 3](#fig3){ref-type="fig"}D and its legend). These data indicated that small CCPs present in WT cells are retained upon AP2 KO.Figure 3Morphological Characterization of CCPs in AP2-WT and AP2-KO Cells(A) Plasma membrane sheets (PMSs) of AP2-WT and AP2-KO MEFs showing examples of clathrin-coated structures (arrowheads, flat clathrin lattices; big arrows, CCPs). Bar, 100 nm.(B) Top: CCS density in AP2-WT and AP2-KO MEFs. Bottom: CCS number was normalized for surface area ([Figure S3](#mmc1){ref-type="supplementary-material"}A; [STAR Methods](#sec4){ref-type="sec"}) and expressed relative to control cells. N represents the number of random images analyzed. Data are represented as mean ± SEM. p values were calculated using two-tailed Student's t test (^∗∗∗^p \< 0.001).(C) Left: size distribution of CCSs in AP2-WT and AP2-KO MEFs ([STAR Methods](#sec4){ref-type="sec"}; [@bib25]). Right: analysis of distribution of CCP areas in AP2-WT and AP2-KO MEFs. Only CCPs \< 0.03 μm^2^ were included in the analysis. N represents the number of CCSs analyzed. p values were calculated using two-tailed Student's t test (^∗∗∗^p \< 0.001).(D) Transmission electron microscopy (TEM) analysis of CCPs in AP2-WT and AP2-KO MEFs. In AP2-KO cells, CCPs appear smaller compared with AP2-WT cells (arrows and insets), as also shown by the morphometric analysis in the right panel. N represents the number of random images analyzed. Bar, 100 nm. p values were calculated using two-tailed Student's t test (^∗∗∗^p \< 0.001).

EGFR-CME Occurs in AP2-KO Cells {#sec2.3}
-------------------------------

The availability of AP2-KO cells afforded the opportunity to test the impact of the bona fide total absence of AP2 on CME of receptors whose internalization proceeds constitutively (exemplified by the TfR) or in a ligand-induced fashion (exemplified by the EGFR).

The measurement of EGFR endocytosis is complicated by the fact that the receptor can be internalized both through CME and through non-clathrin endocytosis (NCE). CME is active already at low doses (1--3 ng/mL) of ligand and persists at higher doses; NCE, conversely, is activated only at higher doses (≥10 ng/mL; [@bib12], [@bib66]). The issue is further compounded by the fact that the presence of the EGFR-NCE pathway is context dependent: some cells (e.g., HeLa cells) possess the pathway whereas others do not ([@bib12], [@bib66]). Experimentally this is reflected in a differential impact of clathrin KD on epidermal growth factor (EGF) internalization performed at different doses of the ligand ([@bib66]). The MEFs under scrutiny here seem to internalize EGFR exclusively through CME, as witnessed by findings that clathrin KD equally reduced the internalization rate by \>85% at both low and high doses of ligand ([Figure S3](#mmc1){ref-type="supplementary-material"}B). Thus, in principle CME-dependent EGFR internalization could be studied in our MEFs at either dose. However, because one of our goals was to compare the AP2-KO setting to the KD settings obtained in different cell lines (in which NCE might be present), all the kinetics internalization experiments with ^125^I-EGF were performed at low ligand (1.5 ng/mL).

Under these conditions, in AP2-KO cells ^125^I-EGF internalization rate was reduced by only ∼50% versus the WT control and further reduced upon clathrin-KD ([Figure 4](#fig4){ref-type="fig"}A, left; [Figure S3](#mmc1){ref-type="supplementary-material"}C). Conversely, ^125^I-Tf (transferrin) internalization was reduced to background levels (defined as the amount measured in clathrin-KD cells) ([Figure 4](#fig4){ref-type="fig"}A, right).Figure 4EGF Internalization in AP2-KO MEFs or upon AP2-KD in Different Cell Contexts(A) ^125^I-EGF (left) and ^125^I-Tf (right) internalization in AP2-WT and AP2-KO MEFs in the presence or absence of clathrin KD. Internalization constants (*K*~e~) are the mean ± SD of two independent experiments. p values were calculated using each pair Student's t test (^∗∗∗^p \< 0.001).(B) Analysis of the impact of AP2μ KD versus clathrin KD in different cell lines as indicated. The number of EGFRs per cell in the different cell lines was measured using ^125^I-EGF saturation binding assay. Kinetics of ^125^I-EGF (1.5 ng/mL) were measured and are reported as internalization constants (*K*~e~). The percentage of AP2-independent EGFR internalization was calculated from the residual *K*~e~ in AP2-KD cells relative to the *K*~e~ in control cells (after subtracting the residual internalization in clathrin KD cells; [@bib66]).(C) TEM analysis of EGFR internalization. AP2-WT and AP2-KO MEFs expressing EGFR under a doxycycline-inducible promoter (AP2-EGFR) were induced with doxycycline. Cells were then subjected to *in vivo* immunolabeling with anti-EGFR 13A9 antibody and 10 nm protein A-gold, stimulated 5 min with EGF (30 ng/mL), and fixed in the presence of ruthenium red, to distinguish PM-connected CCPs (ruthenium red positive) and internalized CCVs (ruthenium red negative) structures. Bar, 100 nm.(D) Morphometrical analysis of (C). Left: CCP number was normalized for the difference in PM length between AP2-KO MEFs versus control (∼1.5-fold increase; see [Figure S3](#mmc1){ref-type="supplementary-material"}A and [STAR Methods](#sec4){ref-type="sec"}) and expressed as relative to control cells. Right: number of gold particles per CCS (CCPs + CCVs). N represents the numbers of random images (left) and CCSs (right) analyzed. Data are expressed as mean ± SEM. p values were calculated using two-tailed Student's t test (^∗^p \< 0.05 and ^∗∗^p \< 0.01).

The results in KO MEFs were virtually indistinguishable from those obtained upon AP2-KD in HeLa cells ([Figure S3](#mmc1){ref-type="supplementary-material"}D; [@bib30], [@bib49]) and in a variety of normal or cancer cell lines of human or murine origin ([Figure 4](#fig4){ref-type="fig"}B).

Together these results allow a number of initial conclusions: (1) the differential impact on Tf versus EGF uptake upon AP2 removal was formally proven in a clean genetic KO background; (2) the KD data are reliable because they phenocopy those obtained in the KO system; and (3) the effects of AP2 removal on cargo uptake are indistinguishable under acute (KD) or chronic (KO) conditions, thereby ruling out a number of potential caveats, such as adaptation in the KO conditions or insufficient targeting or off-target effects in the silencing condition.

EM Characterization of AP2-Independent CME {#sec2.4}
------------------------------------------

To characterize morphologically the EGFR-internalizing structures in AP2-KO cells, we used TEM. The endogenous levels of expression of the EGFR in MEFs were too low to detect a sufficient number of events for quantitative measurements. We circumvented this problem with a twofold strategy: (1) we increased the expression levels of EGFR using a doxycycline-inducible EGFR expression system; upon doxycycline treatment, we obtained EGFR surface levels in MEFs comparable with those detectable in HeLa cells (see [Figure S3](#mmc1){ref-type="supplementary-material"}E); and (2) we stimulated the cells with high doses of EGF (30 ng/mL) because we showed ([Figure S3](#mmc1){ref-type="supplementary-material"}B) that in these cells, only the CME pathway is active. We found, in agreement with the functional data, that EGFR was still recruited to small CCPs and CCVs in AP2-KO MEFs, as visualized either by pre-embedding gold immunolabeling of the EGFR stimulated with unlabeled EGF ([Figure 4](#fig4){ref-type="fig"}C) or by gold labeling with anti-Alexa 488 antibody of cryosections from cells stimulated with Alexa 488-EGF ([Figures S3](#mmc1){ref-type="supplementary-material"}F and S3G; see [STAR Methods](#sec4){ref-type="sec"} and [@bib12]). EGFR-positive structures were reduced by ∼60% versus control cells ([Figure 4](#fig4){ref-type="fig"}D, left). Importantly, the number of gold particles per CCP was significantly reduced ([Figure 4](#fig4){ref-type="fig"}D, right). Thus, a consequence of reduced CCP size is a reduction in cargo loading, under conditions of AP2 KO.

Alternative Endocytic Adaptors Required for AP2-Independent EGFR-CME {#sec2.5}
--------------------------------------------------------------------

How do EGFR-containing CCPs form in the absence of AP2? We investigated the possibility that other AP complexes might functionally substitute for AP2. This was not the case, as clathrin-dependent internalization kinetics of ^125^I-EGF in AP2-KO MEFs were unaffected by KD of the different AP complexes (AP1, AP3, AP4, and AP5) ([Figures 5](#fig5){ref-type="fig"}A and [S4](#mmc1){ref-type="supplementary-material"}A).Figure 5Mechanism of AP2-Independent EGFR-CME: Role of eps15/L1 and epsin1(A) Transient KD of the μ subunit of the indicated AP complexes was performed in AP2-KO MEFs, and *K*~e~ of ^125^I-EGF internalization was calculated. Data are mean ± SD (two replicates).(B) *K*~e~ of ^125^I-EGF internalization in stable eps15/eps15L1-KD HeLa cells transiently depleted of epsin1, alone or in combination with AP2μ, in comparison with AP2-KD and clathrin-KD HeLa cells. Results are mean ± SD of two to eight independent experiments. p values were calculated using each pair Student's t test (^∗∗^p \< 0.01 and ^∗∗∗^p \< 0.001).(C) AP2-WT and AP2-KO MEFs were transiently depleted as indicated. *K*~e~ values of ^125^I-EGF internalization are shown as mean ± SD of two independent experiments. p values were calculated using each pair Student's t test (^∗∗^p \< 0.01 and ^∗∗∗^p \< 0.001).(D) TEM analysis of CCSs in AP2-WT-EGFR MEFs, control or triple KD for eps15, eps15L1, and epsin1, induced with doxycycline (to allow EGFR expression) and stimulated with EGF (30 ng/mL). Morphometrical analysis was performed on EGFR gold-positive structures. Left: CCP number was normalized for the difference in PM length between eps15/eps15L1/epsin1 KD MEFs versus control (∼0.8 decrease; see [Figure S3](#mmc1){ref-type="supplementary-material"}A and [STAR Methods](#sec4){ref-type="sec"}) and expressed relative to control cells. Right: mean number of gold particle per CCS (CCPs + CCVs). N represents the numbers of random images (left panel) and numbers of CCSs (center and right panels) analyzed. Data are expressed as mean ± SEM. p values were calculated using each pair Student's t test (^∗^p \< 0.05).(E) Automated analysis of clathrin-coated structure formation at the plasma membrane from 196 traces containing CLTA-TagRFP and AP2σ-EGFP (clathrin+/AP2+; left panel), 200 traces devoid of AP2σ-EGFP (clathrin+/AP2−; middle panel) from 10 MEF AP2-WT/triple-KD, or 154 traces from 10 MEF AP2-KO/triple-KD cells (right panel).

In search of alternative adaptors, we explored the role of known endocytic proteins, eps15, eps15L1, and epsin1, which we have previously shown to have a redundant role in EGFR-CME ([@bib61], [@bib64]). Indeed, although eps15/eps15L1 KD or epsin1 KD in HeLa cells reduced EGFR-CME by ∼25%, the triple eps15/eps15L1/epsin1 KD (henceforth triple-KD) resulted in a ∼50% decrease in the EGFR internalization rate ([Figures 5](#fig5){ref-type="fig"}B, [S4](#mmc1){ref-type="supplementary-material"}B, and S4C). The addition of epsin2 KD did not worsen the phenotype of the double eps15/eps15L1 KD or of the triple eps15/eps15L1/epsin1 KD (see [Figures S4](#mmc1){ref-type="supplementary-material"}B--S4D and their legends). When the triple-KD was combined with AP2-KD, the EGFR internalization rate was decreased to clathrin-KD levels ([Figures 5](#fig5){ref-type="fig"}B and [S4](#mmc1){ref-type="supplementary-material"}E). Because these data were confirmed in AP2-KO MEFs subjected to triple-KD ([Figures 5](#fig5){ref-type="fig"}C, [S4](#mmc1){ref-type="supplementary-material"}D \[bottom\], and [S4](#mmc1){ref-type="supplementary-material"}F), we propose that eps15/eps15L1/epsin1 are responsible for the residual EGFR-CME observed in the absence of AP2.

EM analysis of triple-KD MEFs (in the AP2-WT-EGFR background) revealed a decrease in the number of EGFR-positive CCPs versus control cells ([Figure 5](#fig5){ref-type="fig"}D, left; [Figure S3](#mmc1){ref-type="supplementary-material"}A), with no apparent defects in CCS size and no reduction in the number of gold particles per CCS ([Figure 5](#fig5){ref-type="fig"}D, center and right), suggesting that the ablation of eps15/eps15L1/epsin1 alters CCP formation and/or stability and affects EGFR-CME but not CCP size and cargo loading.

These data were confirmed by live TIRF microscopy, showing that triple-KD cells display a reduced CCP number per square micrometer (∼60% of the events compared with WT cells), while showing the same CCP fluorescence intensity and lifetime distribution as WT cells ([Figures 5](#fig5){ref-type="fig"}E and [S5](#mmc1){ref-type="supplementary-material"}).

AP2 Is Not Required for EGFR Degradation, but It Is Essential for EGF-Dependent AKT Signaling and Cell Migration {#sec2.6}
----------------------------------------------------------------------------------------------------------------

The previous observations suggest that AP2 is not an absolute requirement for EGFR-CME. In its absence, the internalization of the receptor can still proceed, albeit less efficiently, through a mechanism based on the endocytic accessory proteins eps15/eps15L1 and epsin1. Our data also suggest that AP2, directly or indirectly, controls CCP size, as previously reported ([@bib17], [@bib47]), as supported by the observation that CCPs lacking AP2 are smaller and also contain less EGFRs. To test how these function(s) of AP2 might affect EGF-dependent cellular phenotypes, we performed the following experiments.

First, we investigated the fate of the EGFR after CME in control HeLa cells or upon AP2-KD. To avoid the combined occurrence of EGFR-CME and EGFR-NCE, we used low EGF doses. At low EGF dose in HeLa cells, the EGF-bound receptors internalized via CME are either recycled (about 70%) or targeted to degradation (30%; [@bib65]). However, at low non-saturating EGF concentrations, only a minor fraction of EGFRs are engaged by the ligand; hence, the degradation of that fraction over the total EGFR pool is not readily detectable by immunoblotting, but it could be easily detected by following degradation (and recycling) of the iodinated ligand, which provides accurate quantitative measurements and can be used as a proxy for receptor degradation ([@bib52], [@bib65], [@bib68]). With this assay, we found that in AP2-depleted HeLa cells, despite reduced EGFR-CME, the degradation of the internalized ligand proceeded at a sustained pace and was actually higher than in WT cells, possibly as a consequence of reduced recycling to the PM ([Figure 6](#fig6){ref-type="fig"}A). The minimal interpretation of these data is that the function of AP2 is at least in part dispensable for the execution of one of the major tasks of endocytosis (i.e., long-term attenuation of signaling through receptor degradation). In fact, the opposite seems to be true, namely, AP2 might counteract this function, possibly by augmenting EGFR recycling to the PM, thereby helping modulate EGF-mediated signaling. This possibility was tested by analyzing signaling pathways triggered by the EGFR upon stimulation with low EGF doses in AP2-KO MEFs and AP2-KD HeLa cells. AP2-KO caused a significant attenuation of the phosphorylated AKT signal ([Figures 6](#fig6){ref-type="fig"}B and [S6](#mmc1){ref-type="supplementary-material"}A), a readout for reduced PI3K activity ([@bib71]). The effect appeared to be rather specific for this signaling pathway, as the kinetics of phosphorylation of ERK1/2 and Shc were altered to a much lesser extent in the same cells ([Figure 6](#fig6){ref-type="fig"}B).Figure 6EGF-Dependent Signaling and Migration in AP2-Depleted Cells(A) HeLa cells were subjected to AP2 KD or eps15/L1/epsin1 KD followed by ^125^I-EGF degradation assay at low EGF concentration (1.5 ng/mL; see [STAR Methods](#sec4){ref-type="sec"}). At the indicated time points, (1) degraded EGF (top) represents the TCA soluble fraction of ^125^I-EGF recovered in the medium and intracellularly, and (2) recycled EGF (bottom) represents the TCA insoluble fraction of ^125^I-EGF recovered in the medium. Results are mean ± SD of two independent experiments. p values were calculated using each pair Student's t test (^∗^p \< 0.05 and ^∗∗^p \< 0.01).(B) Top: AP2-WT and AP2-KO MEFs were stimulated with low dose EGF (1.5 ng/mL) for the indicated times. Lysates were subjected to IB with the indicated antibodies. Bottom: quantitation of phosphoAKT signal normalized to total AKT (pAKT/AKT) and represented as percentage of signal in WT cells at 5 min of EGF stimulation. Results are mean ± SD of three independent experiments. p values were calculated using two-tailed Student's t test (^∗^p \< 0.05 versus WT at each time point).(C) Left: HeLa cells were subjected to AP2 KD and/or eps15/L1/epsin1 KD in different combinations, followed by stimulation with low dose EGF (1.5 ng/mL) for the indicated times. IB was as shown. Right: quantitation of phosphoAKT signal normalized to total AKT (pAKT/AKT) and represented as percentage of signal in control cells at 5 min of EGF stimulation. Results are mean ± SD of three independent experiments. p values were calculated using two-tailed Student's t test. ^∗^p \< 0.05 versus control at each time point.(D) Transwell migration assay of AP2 KD and eps15/L1/epsin1 KD HeLa cells under serum-starved (SS) conditions or in the presence of low-dose EGF (1.5 ng/mL) or 10% serum as indicated. Right: quantitation of migrating cells per field. Results are the mean ± SD of two to four independent experiments. p values were calculated using two-tailed Student's t test (^∗^p \< 0.05 versus control in each condition).

The attenuation in the magnitude of AKT phosphorylation was confirmed also in HeLa AP2-KD cells ([Figures 6](#fig6){ref-type="fig"}C and [S6](#mmc1){ref-type="supplementary-material"}B). In contrast, triple-KD had only a minor impact, with a slight increase in the duration of the signal in both cell systems ([Figures 6](#fig6){ref-type="fig"}C, [S6](#mmc1){ref-type="supplementary-material"}B, and S6C).

Given the established causal connection between the PI3K signaling pathway and growth factor-induced directed cell migration ([@bib18], [@bib7]), we tested the impact of AP2 on EGF-mediated chemotaxis. Importantly, AP2-KD in HeLa cells, but not triple-KD, caused a severe impairment in EGF-induced cell migration ([Figure 6](#fig6){ref-type="fig"}D). This defect was not observed when cells migrated in response to serum ([Figure 6](#fig6){ref-type="fig"}D), excluding a general impairment of the chemotactic response in AP2-KD cells and arguing instead for a specific effect of AP2 on EGF-dependent migration.

Ultimately, EGFR activation results in the activation of transcriptional programs involving immediate-early genes (IEGs; at 30--45 min) (i.e., the transcription factors *FOS*, *EGR1*, *JUN*, and *JUNB*) and delayed early genes (DEGs; at 1--2 h), including *DUSP5* and *AREG* ([@bib11], [@bib4], [@bib5]). The kinetics of these events are thought to define the specificity of the downstream transcriptional program ([@bib23]), determining the final cellular outcome.

In agreement with previous reports, IEGs were activated in HeLa cells stimulated with low EGF dose (or with serum), peaking at early time points (30--45 min) ([Figure 7](#fig7){ref-type="fig"}A, upper rows), while DEGs were activated at later times (1--2 h; [Figure 7](#fig7){ref-type="fig"}A, lower rows). No major differences were noticeable between the transcriptional profiles in HeLa and HeLa-AP2-KD cells (under EGF or serum stimulation) ([Figure 7](#fig7){ref-type="fig"}A). Some minor, statistically significant variations were detected, but the magnitude of the effects was minute and probably biologically inconsequential. These data argue that the migratory defect we observed in EGF-stimulated HeLa-AP2-KD cells is largely independent of the EGF-induced early transcriptional program and more likely dependent on the modification of protein activity that characterizes the cytoplasmic component of EGFR signaling.Figure 7EGF-Dependent Transcriptional Output in AP2-Depleted Cells(A) Control or AP2 KD HeLa cells were serum starved overnight followed by stimulation with low-dose EGF (1.5 ng/mL) or with complete medium (10% serum) for the indicated time points. Reported is the mRNA level, assessed by RT-qPCR, of the indicated genes, relative to the unstimulated control and normalized to the levels of the *RPLP0* housekeeping gene. Mean ± SD of two independent experiments with duplicates points is shown.(B) Control or AP2 KO MEFs were serum starved overnight, followed by stimulation with low-dose EGF (1.5 ng/mL) for the indicated time points. Data are expressed as in (A). Mean ± SD of three independent experiments with duplicate points is shown.p values in (A) and (B) were calculated using each pair Student's t test (^∗^p \< 0.05, ^∗∗^p \< 0.01, and ^∗∗∗^p \< 0.001).

The kinetics of EGF-induced transcriptional regulation were comparable between WT MEFs and HeLa cells. In contrast, AP2-KO led to sizable differences in gene expression of a subset of EGF-induced genes, such as (1) reduced induction (i.e., *FOS*), (2) delayed peak of activation (i.e., *JUN*, *DUSP5*, and *AREG*), and (3) increased and sustained activation (i.e., *AREG*) ([Figure 7](#fig7){ref-type="fig"}B). Thus, AP2 KO in MEFs appeared to have a selective effect on the transcription of some EGF-induced genes. In addition, given the differences in the transcriptional impact of AP2 depletion in HeLa versus MEFs, some of the AP2-dependent effects on EGFR long-term signaling could be context specific.

Discussion {#sec3}
==========

We herein report the identification of distinct classes of CCPs that are molecularly distinguished by the presence or lack of AP2. Coupling the use of AP2-KO MEFs, combined with the KD of other adaptor proteins, we dissected the role of AP2-dependent and AP2-independent mechanisms in EGFR internalization and the consequences to the fate, signaling, and biological activities. Our data show that AP2, although not an absolute requirement for EGFR internalization and degradation, is crucial for the magnitude of certain EGFR-dependent signals and for at least one of its associated biological functions (i.e., cell migration).

Distinct Subclasses of CCPs {#sec3.1}
---------------------------

CCPs with different lifetimes and sizes have been detected in cells ([@bib17], [@bib25], [@bib1], [@bib14], [@bib28], [@bib19], [@bib40], [@bib55]). We show that this reflects at least in part a specific molecular composition, defining the existence of at least two types of CCPs detected under physiological unperturbed conditions, characterized by the presence or absence of AP2 and by distinct dynamics and morphological features.

The dependency of the "different" types of pits on various endocytic proteins was explored by taking advantage of molecular genetics. In TIRF experiments, we exploited the genetically engineered deletion of AP2 (AP2-KO) and/or the simultaneous depletion of eps15/L1 and epsin1 adaptors (triple-KD). Our data suggest that (1) AP2 has a role in regulating CCP number, size and lifetime, as previously suggested ([@bib17], [@bib33], [@bib47], [@bib49]) and in agreement with recent findings that AP2 levels are finely regulated during cell differentiation with a consequent impact on CCP dynamics ([@bib17]), and (2) one of the functions of eps15/L1 and epsin1 is to control, to a certain extent, the number of CCPs without affecting their dynamics.

One interesting observation that emerges from our study is that when all adaptor proteins (AP2-KO + triple-KD, henceforth KO/KD; [Figure 5](#fig5){ref-type="fig"}E, right) were removed, some CCPs persisted, although displaying significant reductions in number, size, and lifetime. This could be due to incomplete ablation of eps15/eps15L1/epsin1 or to participation of other endocytic proteins in CCP formation, as also supported by extant literature ([@bib34], [@bib46], [@bib45]). We favor the second possibility, because we showed that in the KO/KD cells, the internalization of the EGFR was reduced to background (clathrin-KD) levels, arguing for efficient ablation of the three adaptors.

AP2 and EGFR Internalization {#sec3.2}
----------------------------

At the functional level, we provided conclusive evidence, in a clean genetic background (i.e., KO of AP2), that the internalization of EGFR versus TfR depends differently on AP2, confirming previous observations ([@bib32], [@bib42], [@bib30], [@bib29], [@bib49]). Although EGFR internalization was reduced but still functional in AP2-KO cells, TfR uptake was reduced to background levels.

One important question is how EGFR-CME proceeds in the absence of AP2. Our results point to a major role of eps15/L1 and epsin1 (by and large acting redundantly among themselves). We do not know whether (and if so how) the "cargo adaptor" function of these proteins is linked to that of regulating CCP number. However, in KO/KD cells ([Figure 5](#fig5){ref-type="fig"}E, right), small short-lived CCPs could still form, although they were incapable of supporting any significant internalization of EGF. Conversely, in the presence of eps15/L1 and epsin1 (AP2-KO), structures indistinguishable from those present in KO/KD cells were clearly sufficient to internalize a significant amount of EGF. Thus, the notion that eps15/L1 and epsin1 function as alternative adaptors to AP2 under physiological conditions is supported by experimental evidence and, at least in the case of epsin1, it was also previously suggested ([@bib21], [@bib8]). However, our data do not imply a scenario of "either AP2 or eps15/L1/epsin1," as they are equally compatible with eps15/L1 and epsin1 participating in all internalization events irrespective of the presence of AP2. Further experiments will be needed to address this issue.

Similarly, the molecular working of eps15/L1/epsin1 in AP2-independent CME remains to be resolved. Of note, these proteins are endowed with a dual biochemical property: (1) harboring ubiquitin-binding domains (UIMs), thereby binding to ubiquitinated proteins, and (2) being monoubiquitinated upon EGF treatment ([@bib53]). One can postulate that through UIMs, they can be recruited to ubiquitinated EGFRs or that through monoubiquitination, they can generate protein-protein interactions, within the endocytic machinery, required for CME. The two functions are not mutually exclusive, and evidence both in favor ([@bib21], [@bib22]) and against ([@bib64], [@bib66]) a critical role of EGFR ubiquitination in CME has been produced. Furthermore, we have previously shown that these adaptor proteins play a critical, redundant, role in CME, dependent on their ability to be ubiquitinated and deubiquitinated ([@bib61]). The issue, therefore, remains open and will require further investigation.

AP2 and EGFR Fate, Signaling, and Biological Activity {#sec3.3}
-----------------------------------------------------

When analyzing the fate of the internalized EGFR in the absence of AP2, we obtained a somewhat surprising result. AP2 appears to be dispensable (at least in part) for one of the major functions of endocytosis in the regulation of EGFR signaling (i.e., attenuation through degradation). This suggests the following interpretation. In the absence of AP2, EGFRs are internalized through eps15/L1/epsin1-dependent CCVs destined to degradation: a situation reminiscent of the ancestral mode based on ubiquitinated adaptors present in yeast ([@bib41]). When AP2 is included, it possibly recruits other proteins responsible for committing the internalizing structures to recycling thereby diverting them from the degradative pathway. The molecular workings of the putative AP2-mediated recycling warrant further investigations.

At the signaling level, the impact of AP2, and presumably of CME, seems to be exerted at multiple levels. When analyzing the effects of AP2 ablation on the more proximal EGFR-dependent signaling, we detected decreased magnitude and duration of certain downstream signaling pathways, in agreement with previous reports showing that EGFR mutants with impaired AP2-binding sites display defects in AKT signaling ([@bib22]). These effects were accompanied by attenuation of EGF-dependent cell migration. This latter effect did not involve perturbations of EGF-dependent transcriptional programs and is therefore likely due to alterations of the initial chain of EGFR-dependent transduction events. In this contention, we note that clustering of signaling receptors into CCPs has been proposed as a mechanism to regulate signaling magnitude at the PM (reviewed by [@bib6]). In particular, EGFR recruitment into CCPs was proposed to spatially constrain otherwise short-lived EGFR dimers and to amplify receptor activation ([@bib57], [@bib31]). Thus, AP2 might be instrumental in assembling PM-based signaling platforms. This possibility is not mutually exclusive with that of prolonged signaling from an early endosomal compartment, which would be sustained through repeated AP2-dependent cycles of internalization and recycling.

Finally, when we analyzed the effects of AP2 depletion on the EGFR-induced transcriptional effects, a clear context dependency emerged. Although we cannot formally rule out that the effects were due to different extents of AP2 ablation, in HeLa AP2-KD versus MEF AP2-KO, we note that all the evidence presented in this study indicates that under our conditions, the KD and the KO phenocopy each other. Thus, we favor the interpretation that there is cell-specific variability in the impact of CME in determining the final EGFR signaling outcome. This is in line with recent findings showing that AP2 levels are variable in different isogenic cellular contexts ([@bib17]), unveiling an unexpected level of plasticity of CME underlying the different specifications required in various cell types.

STAR★Methods {#sec4}
============

Key Resources Table {#sec4.1}
-------------------

REAGENT or RESOURCESOURCEIDENTIFIER**Antibodies***R*abbit polyclonal anti-EGFR (epitope: aa 1172-1186, *Homo sapiens*)In houseN/AMouse anti-eps15 (epitope: aa 2-330, *Mus musculus*)In houseN/ARabbit anti-eps15L1 (epitope: aa 216-266, *Mus musculus*)In houseN/AMouse anti-epsin1/2 (epitope: aa 249-401 of epsin1, *Homo sapiens*)In houseN/AMouse anti-EGFR 13A9GenentechmAbEGFR 13A9Anti-Alexa Fluor 488ThermoFisherCat\# A-11094, RRID:[AB_221544](nif-antibody:AB_221544){#intref0010}Anti-clathrin heavy chain (clone 23)Transduction BDCat\#610499, RRID:[AB_397865](nif-antibody:AB_397865){#intref0015}anti-AP2μTransduction BDCat\#611350, RRID:[AB_398872](nif-antibody:AB_398872){#intref0020}Anti-AP2αSigma-AldrichCat\#A4325,\
RRID:[AB_258156](nif-antibody:AB_258156){#intref0025}Anti-AP2βSigma-AldrichCat\#A4325, RRID:[AB_258156](nif-antibody:AB_258156){#intref0030}Anti-AP2σAbcamCat\#ab128950,\
RRID:[AB_11140842](nif-antibody:AB_11140842){#intref0035}Anti-Phosphotyrosine Antibody, clone 4G10Millipore-MerckCat\#05-321\
RRID:[AB_309678](nif-antibody:AB_309678){#intref0040}Anti-pShcCell SignalingCat\#2434, RRID:[AB_10841301](nif-antibody:AB_10841301){#intref0045}Anti-phospho-AKT (Ser473)Cell SignalingCat\#9271\
RRID:[AB_329825](nif-antibody:AB_329825){#intref0050}Anti-phospho-ERK1/2 (Thr202/Tyr204)Cell SignalingCat\#9101, RRID:[AB_331646](nif-antibody:AB_331646){#intref0055}Anti-total-AKTCell SignalingCat\#9272, RRID:[AB_329827](nif-antibody:AB_329827){#intref0060}Anti-total-ERK1/2Sigma-AldrichCat\# M7927, RRID:[AB_260665](nif-antibody:AB_260665){#intref0065}Anti-pEGFR (Y1173)Cell SignalingCat\# 4407, RRID:[AB_331795](nif-antibody:AB_331795){#intref0070}Anti-GAPDHSanta Cruz BiotechnologyCat\# sc-32233, RRID:[AB_627679](nif-antibody:AB_627679){#intref0075}Anti-tubulinMilliporeCat\# MAB1864, RRID:[AB_2210391](nif-antibody:AB_2210391){#intref0080}Anti-vinculinSigma-AldrichCat\# V9131, RRID:[AB_477629](nif-antibody:AB_477629){#intref0085}**Chemicals, Peptides, and Recombinant Proteins**Recombinant human EGFBPSBioscienceCat\#90201-3^125^I-EGFPerkinElmerCat\#NEX428^125^I-TfPerkinElmerCat\#NEX212Alexa488-EGFMolecular ProbesCat\#E13345Recombinant TAT-Cre recombinaseIn houseN/AProtein-A Gold 10 nmUtrecht UniversityCat\#PAG10nmEM grade glutaraldehydeElectron Microscopy SciencesCat\#16210Sodium cacodylate trihydrateSigmaCat\#C4945Osmium tetroxide 4% SOL.10X10MLElectron Microscopy SciencesCat\#19190Potassium ferricyanideElectron Microscopy SciencesCat\# 20150Ruthenium redSigmaCat\#84071Absolute ethanolSigmaCat\#32221-MEpoxy embedding mediumSigmaCat\#45359-1EA-FSecondary rabbit anti-mouse IgGSigmaCat\# M7023, RRID:[AB_260634](nif-antibody:AB_260634){#intref0090}Collagen I rat tailBD BioscienceCat\#354236**Critical Commercial Assays**RNeasy kitQIAGENCat\#74106QuantiTect Reverse Transcription KitQIAGENCat\#205313Inventoried Taqman assay, EPN1Applied BiosystemsHs00203391_m1Inventoried Taqman assay, EPN2Applied BiosystemsHs00209150_m1Inventoried Taqman assay, EPN3Applied BiosystemsHs00978957_m1Inventoried Taqman assay, Epn1Applied BiosystemsMm01328492_m1Inventoried Taqman assay, Epn2Applied BiosystemsMm00665982_g1Inventoried Taqman assay, Epn3Applied BiosystemsMm00660955_m1Inventoried Taqman assay, CltcApplied BiosystemsMm01303974_m1Inventoried Taqman assay, Ap1m1Applied BiosystemsMm00475912_m1Inventoried Taqman assay, Ap1m2Applied BiosystemsMm00477565_m1Inventoried Taqman assay, Ap2m1Applied BiosystemsMm01702796_g1Inventoried Taqman assay, Ap3m1Applied BiosystemsMm00785907_s1Inventoried Taqman assay, Ap3m2Applied BiosystemsMm00512819_m1Inventoried Taqman assay, Ap4m1Applied BiosystemsMm00480494_m1Inventoried Taqman assay, Ap5m1Applied BiosystemsMm00513794_m1Inventoried Taqman assay, GapdhApplied Biosystemsmm99999915_g1Inventoried Taqman assay, 18SApplied BiosystemsHs99999901_s1miRneasy kitQIAGENCat\#217004SuperScript VILO cDNA Synthesis KitInvitrogenCat\#11754050hsa-Stat3QuantitectQT00068754**Experimental Models: Cell Lines**HeLa cellsIn house ([@bib66])N/ASUM159 cells gene edited to express AP2σ2-EGFP and CLTA-TagRFPThis paperN/AAP2μ^fl/fl^ MEFsThis paperN/A**Oligonucleotides**All Stars control siRNAQIAGENCat \#1027280Stealth RNAi, Clathrin Heavy Chain GAAGAACUCUUUG\
CCCGGAAAUUUAThermoFisherN/ARNAi, AP2α human AAGAGCAUGUGCACGCUGGCCADharmacon ([@bib49])N/AiBONI siRNA, AP2μ human UGACCCGAAAGGCAUCCACCCCCRiboxxN/AStealth RNAi, epsin1 human UUACAAGGCCAUGACGCUGAUGGAGThermoFisherN/AStealth RNAi, epsin1 mouse GACUGGCUCUGAGGCUGUAUCACAAThermoFisherN/AiBONI siRNA, eps15 mouse AAUACUCUCCCUUUGAACUUCCCCCRiboxxN/AiBONI siRNA, eps15L1 mouse UUUCAAAGAUGCCAUCAAACCCCCRiboxxN/AStealth RNAi, epsin 2 human AAGAAAGCCGAAGGGACACAGUUAAThermoFisherN/AiBONI siRNA, AP1μ mouse UUCUUCCGAUACUUGAUGCCCCCRiboxxN/AiBONI siRNA, AP3μ1 mouse UAAAUGGCUUAUACUUCUCCCCCRiboxxN/AiBONI siRNA, AP3μ2 mouse UACAUCCCAAGACAGCAUCCCCCRiboxxN/AiBONI siRNA, AP4μ mouse, pool of four oligosRiboxxN/AiBONI siRNA, AP5μ mouse AUAAUCCAGACCAGUAAGCCCCCRiboxxN/ACustom RT-qPCR primers for EGF-induced transcriptomic analysisSee [Table S1](#mmc1){ref-type="supplementary-material"}See [Table S1](#mmc1){ref-type="supplementary-material"}**Recombinant DNA**pMSCV- CLTA-TagRFP[@bib14]N/ApMSCV-AP2σ2-EGFP[@bib14]N/ApSLIK-EGFRThis paperN/ApSLIK-neo lentiviral vectorAddgene ([@bib63])Cat\#25735pSICOR-shRNA human eps15[@bib64]N/ApSICOR-shRNA human eps15L1[@bib64]N/A**Software and Algorithms**cmeAnalysis software package[@bib1]N/A

Contact for Reagent and Resourse Sharing {#sec4.2}
----------------------------------------

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Sara Sigismund (<sara.sigismund@ieo.it>).

Experimental Model and Subject Details {#sec4.3}
--------------------------------------

HeLa cells (cervical cancer, female) were cultured were grown at 37°C and 5% CO~2~ in GlutaMAX-Minimum Essential Medium (MEM, GIBCO Invitrogen), supplemented with 10% FBS, 1 mM sodium pyruvate (Euroclone), 0.1 mM non-essential amino acids (Euroclone).

Human-derived mostly diploid SUM159 cells (breast cancer, female), gene edited to express AP2σ2-EGFP and CLTA-TagRFP, were grown at 37°C and 5% CO~2~ in DMEM/F12 supplemented with 5% fetal bovine serum (FBS; S11150; Atlanta Biologicals, Flowery Branch, GA), 100 U/ml penicillin and streptomycin (45000-652; VWR International, Radnor, PA), 1 μg/ml hydrocortisone (H4001; Sigma-Aldrich, St. Louis, MO), 5 μg/ml insulin (I9278; Sigma-Aldrich), and 10 mM 4-(2-hydroxyethyl)- 1-piperazineethanesulfonic acid (HEPES; 25-060-CI; Mediatech, Manassas, VA), pH 7.4.

AP2μ^fl/fl^ mouse embryonic fibroblasts (MEFs) were isolated from AP2μ^fl/fl^ mice ([@bib38]) as previously described ([@bib54]), and were spontaneously immortalized after a series of passages in cultures (information about sex of these cells is not available). AP2μ^fl/fl^ MEFs were cultured at 37°C and 5% CO~2~ in Dulbecco's Modified Eagle Medium (DMEM, Lonza) supplemented with 10% FBS and glutamine 2 mM. Immortalized AP2μ^fl/fl^ MEFs were infected with pMSCV retroviral vector expressing AP2σ2-EGFP and CLTA-TagRFP ([@bib14]) and subjected to selection with puromycin for 7 days.

AP2-EGFR MEFs used in EM experiments ([Figures 4](#fig4){ref-type="fig"}C, 4D, and [5](#fig5){ref-type="fig"}D) were generated by infecting AP2-WT MEFs with pSLIK-EGFR inducible lentiviral vector. Forty-eight hours after infection, selection of infected cells was performed by adding neomycin at a concentration of 400 μg/ml for seven days. To induce expression of the EGFR transgene, doxycycline (0.05 μg/ml) was added to cell culture medium for 16 hours.

Human cells were authenticated at each batch freezing by STR profiling (StemElite ID System, Promega). All cell lines were tested for mycoplasma at each batch freezing by PCR ([@bib70]) and biochemical assay (MycoAlert, Lonza).

Method Details {#sec4.4}
--------------

### EGF **concentrations, constructs and antibodies** {#sec4.4.1}

Throughout the manuscript, we have used a low EGF concentration (1.5 ng/ml), unless otherwise indicated.

#### Constructs {#sec4.4.1.1}

pMSCV retroviral vectors expressing AP2σ2-EGFP and CLTA-TagRFP were previously described ([@bib14]); the pSLIK-EGFR vector was generated by subcloning the cDNA coding for human EGFR from a pBABE-based vector ([@bib64]) to the pSLIK-neo lentiviral vector \[for inducible expression in mammalian cells ([@bib63])\].

#### Antibodies {#sec4.4.1.2}

rabbit polyclonal anti-EGFR (epitope: aa 1172-1186, *Homo sapiens*), mouse anti-eps15 (epitope: aa 2-330, *Mus musculus*), rabbit anti-eps15L1 (epitope: aa 216-266, *Mus musculus*), mouse anti-epsin1/2 (epitope: aa 249-401 of epsin1, *Homo sapiens*) were produced in-house and used in IB experiments. Mouse anti-EGFR 13A9 (Genentech) was used to follow endocytosis in *in vivo* EM analyses. Anti-Alexa Fluor 488 (ThermoFisher) was used for cryosection immunolabeling for EM analysis. Other antibodies used in IB are listed in the Key Resources Table.

### CRE treatment of AP2μ^fl/fl^ MEFs {#sec4.4.2}

In order to induce the excision of the AP2 gene and the complete loss of AP2 protein expression, immortalized AP2μ^fl/fl^ MEFs were treated with TAT-CRE recombinase produced in-house to obtain AP2-KO MEFs. Briefly, cells at 50%--60% confluency were washed twice in PBS and treated with 100 μg/mL of TAT-CRE in medium without serum at 37°C. After 1 h incubation, 50 μM chloroquine was added to the medium for an additional hour at 37°C. Cells were then washed twice in PBS and supplemented with normal culture medium. The TAT-CRE treatment was repeated after 3 days; this second round of treatment is recommended to increase the efficiency of recombination. Experiments were performed after 14 days from the first TAT-CRE treatment. The experiments of endocytosis with ^125^I-EGF and ^125^I-Tf were confirmed also in AP2μ^fl/fl^ primary MEFs treated or not with CRE, obtaining the same results as with immortalized MEFs.

### Genome editing of SUM159 cells using the TALEN-based approach {#sec4.4.3}

Human-derived mostly diploid SUM159 cells were homozygously gene edited to express endogenous CLTA-TagRFP together with AP2σ2-EGFP using the TALEN protocol ([@bib60]). The TALEN target sequences were located as follow (the AP2σ2 downstream sequence overlaps with the stop codon underlined):**5′ - \> 3′ targeting sequencesposition relative to stop codonCLTA**TCTCCCTCAAGCAGGCCCCG−9GTGGGACACCTTTGTGATGT+5**AP2σ2**TGGGGCTCGCCTGCCCTCAC−14TGCTGAAACAGCTGC[TGA]{.ul}TG0^∗^

The cells were generated as described ([@bib27], [@bib2]). Briefly, SUM159 cells were co-transfected with the upstream and downstream TALEN targeting sequences and the donor construct coding for the fluorescent protein using TransIT-2020 Transfection Reagent (Mirus Bio LLC, Madison, WI). Cells expressing endogenous clathrin light chain A (CLTA gene) fused to TagRFP at its C terminus and endogenous σ2 of AP-2 (AP2S1 gene) fused at its C terminus with EGFP were sorted by flow cytometry single cell sorting. The insertion of the sequence coding for the fluorescent protein on both alleles was verified by PCR amplification from purified genomic DNA using GoTaq Polymerase (Promega, Madison, WI) using:for the CLTA gene, forward 5′-TTGTTGTTGCTTCCAGGGCA-3′ and reverse 5′-GCCAGGGAGAACACAGTTGA-3′ primersfor the AP2S1 gene, forward 5′-TGAGGTCTGTGTCCCAGCTC-3′ and reverse 5′-GGTTACTCGGGACACACACG-3′ primers.

### TIRF based live-cell microscopy imaging and analysis {#sec4.4.4}

The TIRF microscopy including cell plating was carried as described ([@bib2], [@bib15], [@bib14]) using conditions that would allow detection of the fluorescence intensity from a single molecule of EGFP within a diffraction limited spot.

SUM159 cells were plated onto glass coverslips for 3-4 h whereas MEF cells were plated onto the fibronectin-coated coverslips for 2-3 h, after which they were washed with sterile PBS, transferred onto an Attofluor Cell Chamber (Invitrogen) containing 800 μL of prewarmed MEMα without phenol red (GIBCO) supplemented with 5% FBS and then placed onto a temperature controlled sample holder (20/20 Technology, Wilmington) enclosed placed inside the environmentally controlled chamber of the microscope and time series acquired as described ([@bib2], [@bib15], [@bib14]).

Time series obtained using TIRF microscopy were analyzed using the cmeAnalysis software package ([@bib1]) to trace clathrin-coated structures labeled with CLTA-TagRFP (master channel) and classified as those either containing AP2-σ2-EGFP for at least 40% of their lifetimes (AP2+) or those lacking AP2-σ2-EGFP (AP2-). A range of initial mean squared displacement (MSD) cutoffs (0.010, 0.0155 or 0.02 μm^2^), calculated from the sum of the squares of displacement in x and y between the first and second time points, were used to differentiate relatively immobile clathrin structures initiating at the plasma membrane from those potentially originating at the trans-Golgi network or endosomes. The relatively immobile clathrin traces were then grouped according to their content of AP2 grouped by lifetimes.

### RNAi experiments {#sec4.4.5}

For eps15/eps15L1 double KD, HeLa cells stably depleted using pSICOR-shRNA sequences directed against human eps15 and eps15 L1 were previously described ([@bib64]). These cells were subjected to transient RNAi-mediated knockdown for epsin1, epsin2, clathrin or AP2 in different combinations, as indicated.

RNAi transfections were performed using LipofectAMINE RNAi MAX reagent from Invitrogen, according to manufacturer's instructions. Cells were subjected to double transfection (in both suspension and adhesion), treated with 10 nM RNAi oligo (except for clathrin KD: 24 nM RNAi oligo). Cells were analyzed 4-5 days after transfection.

#### RNAi oligos {#sec4.4.5.1}

The negative control siRNA used in our assays was All Stars from QIAGEN. Other oligos were indicated in the Key Resources Table.

### Quantitative real-time PCR analysis {#sec4.4.6}

Total RNA was extracted from HeLa and MEF cells (control, KD or KO, as indicated) using the RNeasy kit from QIAGEN, according to the manufacturer's protocol. Single stranded cDNA synthesis was performed using the QuantiTect Reverse Transcription Kit (QIAGEN) following manufacturer's instructions.

For the analysis of KD levels by RT-qPCR, the Taqman chemistry (Thermo Fisher Scientific) was used; qPCR instrument was from Applied Biosystems. For the different genes, inventoried Taqman assays (Applied Biosystems) were employed, indicated in the Key Resources Table.

For the transcriptomics analysis of EGF-induced genes ([Figures 7](#fig7){ref-type="fig"}A and 7B), total RNA was reverse-transcribed with SuperScript® VILO cDNA Synthesis Kit (Life Technologies cat.no. 11754050) and measured with Quantifast SYBR green master mix (QIAGEN) in Biorad Cfx384 RT-qPCR detection system. The complete list of primers used in this study is shown in [Table S1](#mmc1){ref-type="supplementary-material"}.

### Cell lysis and immunoblot (IB) {#sec4.4.7}

Cells were lysed in RIPA buffer (50 mM Tris--HCl, 150 mM NaCl, 1 mM EDTA, 1% Triton X-100, 1% sodium deoxycholate, 0.1% SDS); protease inhibitor cocktail (CALBIOCHEM) and phosphatase inhibitors (20 mM sodium pyrophosphate pH 7.5, 50 mM NaF, 2 mM PMSF, 10 mM Na3VO4 pH 7.5) were freshly added.

For EGF stimulation, HeLa or MEF cells were plated on five 10 cm dishes at 50% confluence. The day after, cells were serum starved for 16 h and then stimulated at the indicated time points with 1.5 ng/ml EGF. Total cell lysates (20-30 μg) were loaded onto 4%--20% gradient precast SDS polyacrylamide gels (BIORAD). IB and IP were performed as described ([@bib16], [@bib51]).

### Radioactive assays {#sec4.4.8}

Surface EGFRs were measured by ^125^I-EGF saturation binding as described ([@bib66]). Radioactive internalization assays were performed as described ([@bib12]) with 1.5 ng/ml of ^125^I-EGF or 1 μg/ml of ^125^I-Tf. Results are expressed as the internalization rate constant \[Ke, ([@bib12])\] or as a % of Ke in control cells, as indicated, and are the mean ± SD, calculated on duplicate points of at least two independent experiments.

Degradation of ^125^I-EGF at low dose was measured as described ([@bib65]). In brief, HeLa cells, subjected to KD as indicated, were serum-starved for 2 hours and then incubated with 1.5 ng/ml ^125^I-EGF for 8 min at 37°C, followed by mild acid/salt treatment (0.2 M Na Acetate buffer pH 4.5, 0.5 M NaCl) for 5 min at 4°C to remove bound EGF. ^125^I-EGF-loaded cells were then chased in medium without serum at 37°C for the indicated time points. At the end of each chase time, the medium was collected, the surface-bound ^125^I-EGF was extracted by acid treatment (0.2 M acetic acid pH 2.8, 0.5 M NaCl), and the cells were lysed in 1 mM NaOH. The medium and intracellular lysate fractions were then TCA-precipitated to separate intact from degraded ^125^I-EGF. Non-specific counts were measured for each time point in the presence of a 300-fold excess of cold ligand, and were never \> 3%--10% of the total counts.

### Cell migration assay {#sec4.4.9}

Cell migration assays were performed using a BD Boyden Chamber (BD Biosciences) with 8 μm pores, coated with Collagen I rat tail (10 μg/ml, BD Biosciences). Both chambers were filled with medium. The lower chamber contained serum-starved medium, EGF (1.5 ng/ml) or complete medium. Serum-starved cells (4x10^4^ cells/well) were seeded into the upper chamber of the transwell and allowed to migrate overnight at 37°C. Three replicates for each condition were performed. After the incubation period, cells remaining in the upper chamber were washed away with PBS and removed by a cotton swab. Fixed cells were then stained with DAPI. Cells were counted in three randomly chosen fields using an inverted fluorescence microscope (10X magnification).

### Plasma membrane sheets (PMS) {#sec4.4.10}

PMS were prepared as previously described ([@bib59]). Briefly, formvar/carbon coated nickel grids coated with 1 mg/ml poly-Lysine-D were placed on a pre-wet filter of cellulose acetate on ice. Cells were washed with KSHM buffer (100 mM potassium acetate, 85 mM sucrose, 20 mM HEPES-KOH, pH 7.4, and 1 mM magnesium acetate) and the coverslips were placed cells face down on the EM grids. The excess of buffer was aspirated with a pasture pipette attached to a vacuum pump and a rubber cork was pressed on the coverslip for 10 s. The coverslips were flipped over and the grids were fixed on ice for 30 min in 4% glutaraldehyde in KSHM buffer. PMS were then post-fixed in 1% OsO4 10 s on ice, 1% tannic acid, 1% uranyl acetate and finally rinsed in distilled water and air-dried.

Grids were observed with a LEO 912AB Zeiss Transmission Electron Microscope (Carl Zeiss). Digital micrographs were taken with a 2k × 2k bottom-mounted slow-scan Proscan camera (ProScan) controlled by the EsivisionPro 3.2 software (Soft Imaging System) and analyzed using ImageJ as previously reported ([@bib25]).

### Transmission Electron Microscopy (TEM) {#sec4.4.11}

For TEM analysis, cells treated as indicated were fixed for 1 h at room temperature in 2,5% glutaraldehyde in 100 mM NaCacodylate buffer pH 7.2 and then post-fixed in 1% osmium tetroxide, 1,5% potassium ferricyanide in 100 mM NaCacodylate buffer for 1 hour on ice. Alternatively, in order to discriminate plasma membrane connected pits, cells were fixed with 1.25% glutaraldehyde in 66 mM NaCacodylate buffer containing 0.5mg/ml ruthenium red. After several washes in 150 mM NaCacodylate buffer cells were post fixed in 1.3% osmium tetroxide in a 66 mM NaCacodylate buffer (pH 7.2) containing 0.5 mg/ml ruthenium red for 2 h at room temperature. Both samples were then rinsed in NaCacodylate buffer, washed with distilled water and enbloc stained with 0.5% uranyl acetate in dH~2~0 overnight at 4°C in the dark. Finally, samples were rinsed in dH~2~O, dehydrated with increasing concentrations of ethanol, embedded in Epon and cured in an oven at 60°C for 48 h. Ultrathin sections (70 -- 90 nm) were obtained using an ultramicrotome (UC7, Leica microsystem, Vienna, Austria), collected, stained with uranyl acetate and Sato's lead solutions, and observed in a Transmission Electron Microscope (Leo 912AB, Carl Zeiss, Oberkochen, Germany). Digital micrographs were taken with a 2Kx2K bottom mounted slow-scan camera (ProScan, Lagerlechfeld, Germany) controlled by the EsivisionPro 3.2 software (Soft Imaging System, Münster, Germany). For Morphometrical analysis images of the random selected cellular profiles were analyzed using ImageJ software. CCP density was calculated by dividing the number of CCP for PM length, and further normalized for the variation in cell size observed.

### Pre-embedding immunolabeling {#sec4.4.12}

Serum-starved cells were incubated with anti-EGFR 13A9 antibody, followed by incubation with rabbit anti-mouse, and, finally, with Protein A-gold 10 nm (Utrecht University), 30 min incubation on ice/each step. Cells were then incubated at 37°C for 5 min with 30 ng/ml EGF. A control sample incubated with all reagents except anti-EGFR 13A9 antibody was included in the experiment to control that no internalization was induced by the secondary antibody and Protein A-gold 10 nm ([Figure S3](#mmc1){ref-type="supplementary-material"}F). Cells were then washed in PBS and fixed for 1 h at room temperature in 1.2% glutaraldehyde in 66 mM sodium cacodylate buffer pH 7.2 containing 0.5 mg/ml of ruthenium red. After quick washes with 150 mM sodium cacodylate buffer, the samples were post-fixed in 1.3% osmium tetroxide in a 66 mM sodium cacodylate buffer (pH 7.2) containing 0.5 mg/ml ruthenium red for 2 h at room temperature. Cells were then rinsed with 150 mM NaCacodylate, washed with distilled water and enbloc stained with 0.5% uranyl acetate in dH20 overnight at 4°C in the dark. Finally, samples were rinsed in dH2O, dehydrated with increasing concentrations of ethanol, embedded in Epon and cured in an oven at 60°C for 48 h.

### Anti-EGF immunolabeling of cryosections {#sec4.4.13}

As an independent procedure to visualize EGFR internalizing clathrin-coated pits (CCPs), we performed cryosection experiments ([Figures S3](#mmc1){ref-type="supplementary-material"}F and S3G). Briefly, cells were stimulated with Alexa 488 EGF (30 ng/ml) for 5 min, fixed for 1 h at room temperature (0.2% glutaraldehyde/ 2% paraformaldehyde in PHEM Buffer 0.1 M) and processed as described previously ([@bib67]). Briefly, samples were embedded in 12% gelatin, infiltrated in 2.3 M sucrose and frozen in liquid nitrogen. Cryosections were obtained using a Leica EM FC7 ultramicrotome (Leica microsystem, Vienna, Austria) and collected on 150 mesh formvar carbon-coated copper grids. The labeling procedure was carried out using a rabbit anti-Alexa Fluor 488 antibody (5 μg/ml) in 1% BSA in PBS that was afterward visualized with proteinA conjugated to 10 nm colloidal gold particles (Protein A-gold 10 nm, Utrecht University). Grids were contrasted in a solution of uranyl acetate and methyl-cellulose, air-dried and observed in a Talos L120C transmission electron microscope (Thermo Fisher Scientific).

### Analysis of cell surface area and perimeter {#sec4.4.14}

Cells grown on coverslips were fixed and stained with phalloidin-FITC. Nuclei were counterstained with DAPI. Fluorescence imaging was performed with a Confocal Leica TCS SP5 using a 40X 1.40 NA oil objective and LAS software. Z stacks of different cells were collected. Images were analyzed using ImageJ software. Single cells were selected with ROIs (region of interest) and geometrical properties of each cell (perimeter, basal area, thickness as well as major and minor axis of the best fitting ellipse) were determined. Selected cells were approximated to elliptic cones shape and the total surface area calculated. Per each sample 50 cells were analyzed.

Quantification and Statistical Analysis {#sec4.5}
---------------------------------------

For radioactive assays, statistical analysis was performed using two-tailed Student's t test with Excel when we compared two conditions. When more conditions were compared, Each Pair Student's t test with JMP 10.0 statistical software (SAS Institute, Inc) was performed, which exploits the Fishers LSD test as a follow up to ANOVA.

Quantitation of the blots was performed with Photoshop. Statistical analysis was performed using two-tailed Student's t test with Excel.

For migration assay, statistical analysis was performed using two-tailed Student's t test with Excel.

For PMS and TEM, images were analyzed with ImageJ and statistical analysis was performed using GraphPad Prism. Two tailed paired Student's t test was used to calculate statistical significance among different samples.
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